Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Destiny Pharma's XF-73 Being Studied For Diabetic Foot Ulcers, Burns Too

Executive Summary

One year after its IPO, UK-based Destiny Pharma's CEO tells Scrip it's on track with US development of its lead antimicrobial asset XF-73 for prevention of post-operative infections and will also develop a new formulation to treat infections in diabetic foot ulcers and burn wounds.

You may also be interested in...

Pharma Welcomes UK Incentive Plan To Tackle AMR

There has been an enthusiastic response from industry to the news that NICE and NHS England are to explore a new payment model that pays pharmaceutical companies based on how valuable their medicines are to the country's health service, rather than on the quantity of antibiotics sold.

Patient-Centric: Evotec’s CSO Explains R&D Strategy

Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.

Novo Nordisk, Evotec Link Around Chronic Kidney Disease

Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts